The International Diabetes Federation (IDF) estimates that by 2025, more than 380 million people worldwide will suffer from Type 2 diabetes which is regarded as a chronic syndrome linked to premature death. The disease is characterized by increased blood glucose levels due to poor secretion of insulin from pancreas.
GlaxoSmithKline, one of the world’s leading research-based pharmaceutical and healthcare companies, brings slight relief to our sweet blood by announcing the Phase III clinical trial of its newest product Syncria(R)(Albiglutide). The programme will test the efficacy, safety and tolerability of the drug on men and women with type 2 diabetes.
Albiglutide is the investigational medication available in injection form. It contains Glucagon-like peptide 1 or GLP-1, a peptide that acts throughout the body to help maintain normal blood-sugar levels and to control appetite.
GLP-1 is present naturally in humans which controls blood glucose levels but its secretion becomes less in persons suffering from type 2 diabetes. Albiglutide is the only medication which fuses human GLP-1 to human albumin. It is designed to have an extended duration of action and allow for weekly or less-frequent injections.
The Phase III programme for albiglutide will begin with five studies in early 2009. The objective of the programme is to demonstrate durable efficacy and cardiovascular safety of albiglutide as mono- and add-on therapy, in patients with type 2 diabetes.
Source:Cloud Computing Journal
Filed under Diabetes, Diabetes Drug, NIDDM | Tags: clinical trial, Diabetes, Diabetes Drug, diabetes type 2, GlaxoSmithKline., healthcare, Phase III clinical trial, Syncria(R)(albiglutide) | Comment Below